ArsenalBio Secures $325M with Regeneron, BMS Backing
ArsenalBio raises $325M to advance solid tumor CAR-T therapies. Focus on kidney, prostate cancer with innovative genomic technology.
- Latest
- Trending
ArsenalBio raises $325M to advance solid tumor CAR-T therapies. Focus on kidney, prostate cancer with innovative genomic technology.
Genmab's H1 2024 results show 36% revenue growth; DARZALEX sales surge, and strategic acquisition of ProfoundBio boosts future potential.
Aditxt (ADTX) stock is soaring after a major update on a clinical trial for early ovarian cancer detection, driving heavy ...
Consider investing in AbbVie and e.l.f., two names with significant growth potential in 2024. AbbVie shines as a quality business ...
BioVaxys Technology Corp. finalizes agreement to acquire IMV Inc.'s immunotherapy technology portfolio, expanding its cancer vaccine portfolio and positioning itself ...
Anixa Biosciences advances Phase 1 clinical trial for ovarian cancer therapy, increasing dosage and showing promising results. Market responds positively ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.